ユニサイシブ・セラピューティクス
Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.54 | $0 | -$6M |
| 2025 Q4 | -0.66 | $0 | -$8M |
| 2025 Q3 | -0.33 | $0 | -$6M |
| 2025 Q2 | -0.52 | $0 | -$8M |
| 2025 Q1 | 0.04 | $0 | -$9M |
| 2024 Q4 | -2.00 | $0 | -$7M |
| 2024 Q3 |
| -0.46 |
| $0 |
| -$9M |
| 2024 Q2 | 0.08 | $0 | -$6M |